Thomas Bell Named Director of Toxicology Services at SNBL USA, Ltd.

Everett, WA – July 6, 2011 – SNBL USA, one of the nation’s leading preclinical testing companies, announced today that Thomas Bell has joined the executive team to serve in the newly created role of Director of Toxicology Services. In this position Tom will assume leadership for all scientific services activities and personnel and will be responsible for strategic plans, policies, and procedures at all levels to ensure SNBL USA’s toxicology services meet or exceed customer’s needs, timelines, quality, and regulatory requirements.

“We are fortunate to have to have Tom on board as this role represents our commitment to establishing SNBL USA as a leading, innovative preclinical CRO while at the same time staying dedicated to maintaining regulatory compliance across the board,” said Dr. Thomas Beck, SNBL USA president and COO. “Tom’s wide range of technical expertise in the biopharmaceutical industry makes him an ideal director for the team as we continue on-going quality improvement initiatives and offering our clients quality science and service.”

Thomas Bell has over 20 years industry experience in the toxicology field and is well-versed in many areas of the drug development process. Prior to joining SNBL USA, he has held various positions including Production Manager at Marshall Bioresources; Manager of Toxicology Resources at Wyeth Research/Pfizer; Technical Resources Manager, Reproductive Toxicology Unit Coordinator, Scientist, and Staff Toxicologist at Wyeth Ayerst. Mr. Bell holds two Bachelor of Science degrees in Biology and History, respectively, from Worcester State College and is an AALAS-Certified Manager of Animal Resources.

For more information regarding SNBL USA toxicology services or its preclinical services in general, contact SNBL USA today via info@snblusa.com or 425.322.1950.

About SNBL USA, Ltd.

Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. SNBL USA’s Laboratory Services division intelligently applies extensive experience, comprehensive scientific capabilities, and modern technology to bring outstanding support to all client research. SNBL USA SRC complements SNBL USA in providing quality NHP resources. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.

SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. Established in 1957, SNBL currently employs approximately 2,000 team members worldwide and provides full service drug development capabilities ranging from preclinical through clinical services.